Highest-materiality recent filing
Hyperion DeFi signs new employment pacts with CEO Jung, CFO Knox, GC Rubenstein
CEO Jung gets target bonus upon termination within 12 months after change in control, plus prior severance.
All five director nominees elected with >1.5M votes for each; broker non-votes ~4.2M.
Hyperion DeFi to wind down Native Markets and Felix agreements; reposition 800k HYPE tokens
Native Markets terminated Temporary Use Agreement effective June 18, 2026; Company received all fees and 300k HYPE tokens returned on June 3.
Hyperion DeFi Q1 2026 record net income $8.84M; raises FY 2026 adjusted gross profit guidance ~20%
GAAP net income $8.84M vs. loss of $39.8M in Q4 2025; non-GAAP adjusted EBITDA $19.5M.
Hyperion DeFi prices 2.78M share offering at $3.60, expects ~$10M gross
Offers 2,777,778 shares at $3.60 per share; sole underwriter Chardan Capital Markets.
Q4 revenue $496K (+64% QoQ); Adjusted Gross Profit $821K (+87% QoQ).
Hyperion DeFi appoints Hyunsu Jung as permanent CEO; employment agreement through January 2029
Hyunsu Jung (formerly interim CEO since Sept 2025) named permanent CEO effective Jan 1, 2026; base salary $520K.
HYPE-heavy treasury strategy exposes assets to extreme price volatility; price decline could materially impact financial condition.
Hyperion DeFi enters $500M ATM equity sales agreement with Cantor, Chardan
Sales Agreement dated Nov 14, 2025 with Cantor Fitzgerald & Co. and Chardan Capital Markets LLC.
Hyperion DeFi reports record Q3 net income of $6.6M; initiates Q4 guidance of 31-43% QoQ growth
Net income of $6.6M vs ($7.9M) loss in Q3'24; basic EPS $0.26, diluted $0.05.
Hyperion DeFi partners with Felix, allocates 500k HYPE to launch HIP-3 perpetual futures market
Hyperion entered a Joint Validator Agreement with Kinetiq and Pier Two, staking 10,000 HYPE for a validator node on Hyperliquid.
Director Michael Rowe resigns from Hyperion DeFi Board
Michael Rowe resigned from the Board of Directors effective September 30, 2025.
Hyperion DeFi appoints PayPal veteran David Knox as CFO, effective immediately
David Knox, former PayPal Head of Capital Markets and Head of Finance for Global Credit & Financial Services, named CFO.
Hyperion DeFi ups ATM offering capacity to $100M; has raised ~$29M to date
Amended sales agreement with Chardan Capital Markets increases aggregate offering price from $50M to $100M.
Hyperion DeFi CEO Michael Rowe resigns; Hyunsu Jung named interim CEO; board appoints Happy Walters
Michael Rowe resigned as CEO effective immediately; Hyunsu Jung (CIO & director) named interim CEO, CFO, Treasurer, and Secretary.
Hyperion DeFi shareholders approve doubling authorized shares; written consent proposal fails
Authorized common shares doubled from 300M to 600M; preferred from 6M to 60M via charter amendment filed Aug 19.
Hyperion DeFi reports Q2 net loss of $8.8M, acquires >1.5M HYPE tokens
Net loss of $8.8M ($2.50 per share) vs $11.1M ($16.65) in Q2 2024; cash $7.5M as of June 30.
Eyenovia rebrands to Hyperion DeFi, ticker to HYPD; COO departs amid crypto treasury pivot
Name change from Eyenovia to Hyperion DeFi effective July 1, 2025; new ticker HYPD on Nasdaq July 3.
Eyenovia pivots to HYPE cryptocurrency treasury; launches validator with Kinetiq
Eyenovia adopts HYPE as strategic treasury asset; first US public company to do so.
Eyenovia raises $50M to acquire HYPE tokens, shifts to crypto treasury strategy; appoints new CIO
$50M PIPE for HYPE tokens; warrants could raise ~$150M more if exercised at $3.25/share.
Third Amendment caps lender beneficial ownership at 9.99% (adjustable to 19.99% with 61-day notice) on conversion of up to $10M principal.
Eyenovia Reports Q1 2025 Financial Results, Provides Merger and Optejet Development Update
Net loss narrowed to $3.5 million ($1.59 per share) versus $10.9 million ($18.75 per share) in Q1 2024.
Eyenovia receives Nasdaq deficiency notice for equity below $2.5M minimum
Nasdaq notified Eyenovia that stockholders' equity as of Dec 31, 2024 was below the $2.5M minimum required.
Eyenovia appoints CBIZ CPAs as auditor after Marcum resignation; going concern flagged
Marcum LLP resigned as independent auditor; CBIZ CPAs P.C. engaged effective May 2, 2025.
Eyenovia enters non-binding LOI for reverse merger with Betaliq; EYEN holders to own ~16.3%
Reverse merger: Betaliq stockholders would own ~83.7% of combined company; Eyenovia holders ~16.3% on fully diluted basis.
Eyenovia regains Nasdaq minimum bid compliance after reverse stock split
Nasdaq notified Eyenovia on Feb 25, 2025 that it regained compliance with the $1.00 minimum bid requirement as of Feb 20.
Deferred principal and interest payments until Sept 30, 2025; interest rate is prime + 4.45% (floor 7%).
Eyenovia files 1-for-80 reverse stock split to regain Nasdaq minimum bid compliance
Reverse stock split 1-for-80 effective Jan 31, 2025 at 4:00 p.m. ET.
Reverse split at 1-for-80 ratio reduces outstanding shares from ~167.5M to ~2.1M; effective 4:00 pm ET Jan 31, 2025.
Eyenovia shareholders approve reverse stock split (1:40-1:80) and share issuances
Reverse stock split amendment approved with 45.3M votes for, 12.6M against; ratio between 1:40 and 1:80.
Eyenovia induces warrant exercise raising $1.0M; issues new warrants with 200% coverage at $0.0659
Investor exercised 15,769,445 existing warrants at reduced price of $0.0659, gross proceeds ~$1.0M.
Eyenovia replaces ATM agent, reports $2.2M cash vs $10.1M debt
New ATM agreement with Chardan Capital Markets for up to $50M, replacing Leerink Partners; 3% commission.
Eyenovia receives Nasdaq delisting notice due to low stock price; plans to appeal
Nasdaq determined to delist Eyenovia's common stock because closing bid price was $0.10 or less for 10 consecutive trading days as of December 11, 2024.
Eyenovia raises $1.9M via registered direct offering of common stock and warrants at $0.0969/share
Offering of 20,085,025 shares/pre-funded warrants and 40,170,050 warrants, combined price $0.0969 per unit.
Eyenovia prices $1.3M registered direct offering of 12M shares plus warrants at $0.1076/share
Offering consists of 12,081,785 shares/pre-funded warrants and 24,163,570 warrants; combined price $0.1076 per share+accompanying warrant.
Eyenovia amends debt facility, issues 1.9M shares to lenders, CFO resigns
First Amendment defers principal & interest payments on $10.1M facility until end of Feb 2025; deferred interest added to principal.
Eyenovia reports $0.7M cash, $10.1M debt; in restructuring talks with Avenue Capital
Cash and cash equivalents of $0.7M as of November 19, 2024; $10.1M principal and accrued interest due under Loan and Security Agreement.
Eyenovia Phase 3 CHAPERONE myopia trial fails; cuts 50% staff, explores strategic options
Independent DRC found CHAPERONE not meeting primary endpoint of <0.5 diopter progression over 3 years; study terminated.
Eyenovia Q3 2024 net loss $7.9M; advances MicroPine Phase 3 and launches clobetasol
Net loss of $7.9M ($0.11/share) vs $7.3M ($0.18/share) in Q3 2023; SG&A up 27% to $3.7M.
Eyenovia prices $4M registered direct offering of common stock and warrants at $0.46/unit
8,695,653 shares (or equivalents) and 8,695,653 warrants sold at $0.46 per share and accompanying warrant.
Eyenovia receives Nasdaq bid price deficiency notice; has until March 17, 2025 to regain compliance
Received Nasdaq deficiency letter on Sept 18, 2024; bid price below $1.00 for 30 consecutive business days.
Eyenovia appoints Andrew Jones as CFO; John Gandolfo retires through Nov 2024
John Gandolfo retired as CFO, Treasurer, and Secretary on Aug 30, 2024; will remain an employee through Nov 30, 2024 for transition.
Eyenovia posts updated corporate presentation; no material new details disclosed
Eyenovia released an updated corporate investor presentation on August 23, 2024.
Eyenovia prices public offering of 12.85M shares at $0.40 for ~$5.14M gross proceeds
Priced 12,850,000 common shares at $0.40 per share; expected to close August 22, 2024.
Eyenovia Q2 net loss $11.1M; plans Gen-2 Optejet submission 2025 with Mydcombi
Net loss $11.1M ($0.21/share) vs $6.2M ($0.16/share) in Q2 2023; includes $2.9M MicroPine license reacquisition expense.
Eyenovia regains Nasdaq minimum bid price compliance after 10-day stretch over $1.00
Received Nasdaq confirmation on July 26, 2024 that compliance with Listing Rule 5550(a)(2) is regained.
Eyenovia receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq notified Eyenovia that its common stock closed below $1.00 for 30 consecutive business days.
Eyenovia raises ~$5M via registered direct offering of shares and warrants; amends prior warrants
Offering of 7,575,757 shares plus warrants to purchase 7,575,757 shares at $0.66 per unit.
Eyenovia shareholders approve increase in authorized common stock from 90M to 300M
Charter amendment to increase authorized common shares from 90M to 300M approved by 19.6M for, 6.9M against, 2.7M abstain.
MicroPine Phase 3 CHAPERONE interim DMC review expected 4Q 2024; SAE rate <1 per 1,000 patient-months, all unrelated.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
On June 17, 2025, the Board of Directors (the “Board”) of the Company appointed Hyunsu Jung to the position of Chief Investment Officer and to serve on the Board, effective immediately.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.
Andrew D. Jones transitioned out of his position as Chief Financial Officer, Treasurer and Secretary of the Company
Also, effective August 30, 2024, the Board of Directors of the Company (the “Board”) appointed Andrew D. Jones to the positions of Chief Financial Officer, Treasurer and Secretary of the Company.
John Gandolfo retired from his positions as Chief Financial Officer, Treasurer and Secretary of Eyenovia, Inc. (the “Company”).
On November 10, 2023, the Board of Directors (the “Board”) of the Company appointed Michael Geltzeiler to serve on the Board and as the Chair of the Audit Committee of the Board (the “Audit Committee”), in each case, effective November 14, 2023.
On February 28, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing the resignation of Stephen Benjamin from the Board of Directors (the “Board”) and the Audit Committee, effective as of February 27, 2023.
On December 5, 2022, the Board of Directors (the “Board”) of Eyenovia, Inc. (the “Company”) appointed Bren Kern, the Company’s current Senior Vice President of Manufacturing and Operations, as the Company’s Chief Operating Officer, effective January 1, 2023.
In addition, the Company hereby announces the resignation of Dr. Julia Haller from the Board, effective as of December 6, 2022.
Mr. Rowe will also serve as a member of the Board, effective as of August 1, 2022
Max materiality 0.95 · Median 0.65 · Most common event other_material